Pharmaceuticals: Commission refines intellectual property rules

Pharmaceuticals 2018 European Commission

The EPO – European Patent Office, has announced the 15 inventors short-listed for this prestigious prize – pioneers in a range of technical fields, from green plastics and oil-spill clean-up, to pharmaceuticals, medical imaging and satellite navigation. Gert-Jan Gruter (The Netherlands), nominated for the European Inventor Award 2017 in the category “Small and medium-sized enterprises – SMEs”. © European Patent Organisation , 2017 / Source: EC – Audiovisual Service / Photo: Heinz Troll

This article is brought to you in association with the European Commission.

The Commission is proposing a targeted adjustment to intellectual property rules to help Europe’s pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

The EU has a strong intellectual property rights framework in place which protects Europe’s know-how and sustains the pharmaceutical industry’s world-class innovation capacity. To improve the current system further and remove a major competitive disadvantage of EU manufacturers, the Commission proposes a targeted amendment: the so-called ‘export manufacturing waiver’ to Supplementary Protection Certificates.

Supplementary Protection Certificates (SPCs) extend patent protection for medicinal products which must undergo lengthy testing and clinical trials prior to obtaining regulatory marketing approval. Thanks to the waiver, in the future EU-based companies will be entitled to manufacture a generic or biosimilar version of an SPC-protected medicine during the term of the certificate, if done exclusively for the purpose of exporting to a non-EU market where protection has expired or never existed. The waiver will support Europe’s pioneering role in pharmaceutical research and development.

Vice-President Jyrki Katainen, responsible for Jobs, Growth Investment and Competitiveness, said: “Europe is and should remain at the forefront of pharmaceutical research and manufacturing. Our rules on intellectual property protection of pharmaceuticals promote innovation and creativity. We are committed to the core rights and the length of this protection, which remain unchanged. Today we are proposing a well-calibrated adjustment to the current regime to remove a legal barrier that was preventing our companies from competing on equal terms on global markets where competition is fierce. We want to make sure that our pharmaceutical industry reaps the benefits of such competition.”

Elżbieta Bieńkowska, Commissioner for Internal Market, Industry, Entrepreneurship and SMEs, added: “Today’s proposal strikes a balance between the imperative to ensure the attractiveness of Europe for innovative pharmaceutical companies and the urgency to allow EU based generics and biosimilar to compete on the global markets. This will help create growth and high-skilled jobs in the EU. It could generate €1 billion net additional sales per year and up to 25 000 new jobs over 10 years. It will particularly benefit the many small and medium-sized enterprises in the field. In the medium term, more competition will improve patients’ access to a wider choice of medicines and alleviate public budgets.”

With the waiver, intellectual property (IP) protection for medicine production in Europe will remain the strongest in the world. SPC-protected medicines will retain their full market exclusivity in the EU.

The proposal is accompanied by a series of safeguards which will create transparency and prevent IP-infringing products from entering Member State markets. It goes hand in hand with other EU initiatives to defend Europe’s know-how and innovation leadership and protect patients against counterfeited medicines. It also complements the EU’s overall approach to ensure free and fair trade, characterised by open markets, for EU-based manufacturers.

Today’s proposal amends Regulation 469/2009 on the supplementary protection certificate for medicinal products. Once adopted by the European Parliament and Council, it will be directly applicable in all EU Member States.

Background

EU and global pharmaceutical markets are undergoing profound changes. Global demand for medicines has increased massively, reaching over €1 trillion in 2017. Alongside this, there is a shift towards an ever-greater market share for generics and biosimilars. Traditionally the EU has played a pioneering role in pharmaceutical research and development, including generic medicines and biosimilars. But this leadership position is under threat.

Supplementary protection certificates (SPCs) are an intellectual property right first introduced in the EU in 1992 as an extension to a patent right. Pharmaceutical SPCs aim to offset the loss of effective patent protection for medicines that occurs due to the compulsory lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. An SPC can extend a patent right for a maximum of five years.

EU SPC rules are the strongest in the world. While they aim to reward investment in innovation and protect intellectual property, SPCs can put EU based manufacturers of generics and biosimilar at a disadvantage with non-EU based industry, thereby preventing further innovation and job creation in Europe. Indeed, during the SPC period of protection of the product in the EU, EU-based manufacturers of generic and/or biosimilar-related products cannot currently manufacture for any purpose, including export outside the EUto countries where SPC protection has expired or does not exist, while manufacturers based in those non-EU countries can do so. This major competitive disadvantage entails a risk of delocalisation of manufacturing and loss of investment in Europe. The certificate also makes it more difficult for EU manufacturers to enter the EU market immediately after its expiry, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed.

Many SPC protections will start to lapse from 2020, as a significant number of medicinal products will enter the public domain, since their patent or SPC terms will expire. This development will generate significant new market opportunities for generics, and for biosimilars in particular. There is an urgent need to adjust the existing regulation to this situation, as the markets for generics and biosimilars are highly competitive and steadily growing and the investment decisions on the localisation of the production are being made well in advance.

Today’s proposal was announced in the Commission’s 2015 Single Market Strategy, and follows various studies, an extensive consultation and a European Parliament resolution endorsing the need to introduce before 2019 an SPC manufacturing waiver.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

MasterCard at European Business Summit 2015: A focus on innovation will drive inclusive economic growth for Europe

Children are still dying in Yemen war, despite partial ceasefire, says UNICEF chief

London wants new skyscrapers to protect cyclists from wind tunnels

Security Union: Commission receives mandate to start negotiating international rules for obtaining electronic evidence

Release of prize-winning Reuters journalists in Myanmar welcomed by UN

The EU’s outermost regions: strengthened partnership bears fruit

EU prolongs economic sanctions on Russia by six months

European Citizens’ Initiative: Commission decides to register ‘Right to Cure’ initiative

10 lessons from the COVID-19 frontline for a more gender-equal world

The European Parliament rewrites the EU budget in a bright day for the Union

Why exchange programs are essential for the medical students of the 21st century

Doctors vs. Industry 4.0: who will win?

Western Balkans: MEPs take stock of 2018 progress

World Health Organization calls crisis meeting over deadly Ebola outbreak in DR Congo

Business uncertainty rises as US grants only temporary exception to EU for steel and aluminium tariffs

Cybersecurity needs a holistic approach. Here are three ways to build protection

Commission offers discount on fines to banks for competition infringements

Oleg Sentsov awarded the 2018 Sakharov Prize

These 5 charts show our shifting behaviour around coronavirus

Conflict, climate change among factors that increase ‘desperation that enables human trafficking to flourish’, says UN chief

Nine children killed or maimed in Afghanistan every day: UN Children’s Fund

Although Greece is struggling to pay salaries and pensions Varoufakis is “optimistic”; the Sting reports live from EBS 2015

Draghi repels Trump’s threats, rejects Schauble’s dictums

This surgeon runs a makeshift hospital for over 200,000 people

UN chief extends condolences to families of China landslide casualties

Education in Emergencies: EU announces record humanitarian funding for 2019 and launches #RaiseYourPencil Campaign

A European Discovers China: 3 First Impressions

Why philanthropy for – and by – Africans is the future

Voices of Afghan women ‘must be heard at the table in the peace process and beyond’ UN deputy chief tells Security Council

Drinking water: new plans to improve tap water quality and cut plastic litter

JADE Team at the European Business Summit 2017

Respect people’s peaceful assembly and fair trail rights, UN human rights wing urges Nicaragua

The consequences of Brexit seen by a European young entrepreneur

The EU Spring Summit set to challenge austerity

How India is solving its cooling challenge

Why the 21st century’s biggest health challenge is our shared responsibility

These entrepreneurs are turning discarded fishing nets into surfboards and swimwear

Building cybersecurity capacity through benchmarking: the Global Cybersecurity Index

Ministers for Youth miss the opportunity to improve social inclusion of young people

Harnessing the power of nature in the fight against climate change

Nearly three million more displaced year-on-year, warns refugee agency chief, but solutions are within reach

UN commission agrees roadmap on ensuring women’s social protection, mobility, safety, and access to economic opportunities

EU confronts environmental threats as global leaders attempt to revive the global sentiment at NYC climate week

Why remote working doesn’t have to mean alienated employees

UN chief seeking ‘renewed commitment’ to global rules and values, as world leaders head to New York

Strong multilateral institutions key to tackling world’s dramatic challenges, UN chief says In Moscow

We had the hottest June ever this year – this is what happened around the world

Human Rights and Democracy: striving for dignity and equality around the world

China, forever new adventures

Employment and Social Developments in Europe: 2018 review confirms positive trends but highlights challenges, in particular linked to automation and digitalisation

Main results of Asia-Europe Meeting (ASEM) – 18-19/10/2018

UN expert condemns new sentence for jailed Venezuelan judge as ‘another instance of reprisal’

This new programme could hold the key to solving global health challenges

Two-thirds of employees would trust a robot boss more than a real one

LGBTQ+ inclusion on the other side of the screen

How communities are dealing with economy, society and education in COVID-19 crisis     

A Sting Exclusive: EU Commission’s Vice President Šefčovič accentuates the importance of innovation to EU’s Energy Union

November infringements package: key decisions

Bigotry makes politicians ‘complicit in the violence that follows’ : UN independent experts

Acute food insecurity ‘far too high’ UN agency warns, as 113 million go hungry

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s